Skip to Main Content

Amid increased concerns over a lack of transparency in clinical trials, a new study found that one in five primary endpoints were changed after a late-stage study had begun, and 70% of the trials examined did not include information about primary endpoint changes in articles published in medical journals.

Specifically, 145 of 755 randomized controlled trials for cancer medications — or 19% — had changes to the primary endpoints when using at least one of three different methods to detect any differences. Of the 145 trials with changes, 102 — or 70% — did not disclose them in published manuscripts.


As a result, the findings raised questions about the quality of the clinical trials, as well as a risk that the results reflected bias toward selecting a particular outcome, according to the authors of the study, which was published in JAMA Network Open.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.